Area of investment and support

Area of investment and support: MRC Proof of Concept (formerly Developmental Pathway Funding Scheme or DPFS)

This scheme aims to drive fundamental discoveries stemming from MRC discovery research and the wider academic community along the developmental pathway towards patient benefit and or commercialisation.

Budget:
£35 to 40 million a year
Duration:
Ongoing
Partners involved:
Medical Research Council (MRC)

The scope and what we're doing

MRC Proof of Concept (formerly titled the Developmental Pathway Funding Scheme or DPFS) is the core MRC translational research scheme and forms a key part of our clinical and translational research strategy.

The aim of the scheme is to advance fundamental discoveries arising from academic research along the developmental pathway towards patient benefit and or commercialisation.

All disease areas are eligible for support from the scheme, and applications to this scheme can focus on the development of any innovative solution that aims to improve the prevention, diagnosis, prognosis or treatment of significant health needs. We also support projects that focus on developing research tools or platform technologies that increase the efficiency of developing interventions.

Individual projects can start and finish at any point along the translational pathway from prototype development, through pre-clinical refinement, to early-phase clinical studies (up to and including phase IIa).

Collaborations

MRC encourages partnerships in applications, with charities or industry, where these add value to the project. If your application involves a collaboration with one or more industry partners, review the MRC Industry Collaboration Framework.

Opportunities, support and resources available

Funding opportunities

This ongoing scheme has three outline application deadlines per year in March, July and November.

Both broad guidance on assessment criteria and governance, and specific guidance on preparation of MRC Proof of Concept stage one proposals, are available in the MRC Proof of Concept funding opportunity.

Stage two guidance is provided to successful applicants with the stage one application feedback.

Support

MRC hosted a webinar providing an overview of the MRC Proof of Concept funding opportunity, including information on the assessment process and tips for writing a successful stage one application. Details can be found in the MRC Proof of Concept funding opportunity under ‘Additional info’.

Resources

The following organisations provide resources that you may find useful. We encourage you to visit their websites when preparing an application.

The MRC Centre for Research Policy works with the research community to develop and implement policy that encourages good research practice, by promoting ethical and responsible research conduct.

The National Institute for Health Research (NIHR) provides a clinical trials toolkit that gives practical advice to those planning or running clinical trials in the UK.

The MHRA Innovation Office provides free advice to clarify regulatory requirements from an early stage of product development.

Applicants considering a drug repurposing project may wish to explore the Repurposing Medicines Toolkit, developed by MRC and LifeArc.

The MRC Methodology Hubs provide guidance and resources to help researchers design, conduct and analyse clinical trials, particularly in complex areas.

The Innovation Hubs for Gene Therapies support academic-led clinical development of gene therapies through manufacturing of clinical grade viral vector, translational and regulatory support, and process development support.

MRC and NIHR work in collaboration to provide a spectrum of funding opportunities for clinical studies and trials. To support applicants planning a clinical study or trial, a guidance document has been prepared comparing the typical characteristics of projects supported by the MRC Experimental Medicine, MRC Proof of Concept, NIHR Efficacy Mechanism and Evaluation, and NIHR Healthcare Technology Assessment.

To support applicants applying to MRC Proof of Concept for funding to develop and validate clinical tests, supplementary applicant guidance has been prepared.

Past projects, outcomes and impact

DPFS (now MRC Proof of Concept) was established in 2008 and, since then, around 380 projects have been awarded funding with a total budget of around £460 million.

Find details about successful applications to DPFS and MRC Proof of Concept.

Search for more detailed information on funded projects on Gateway to Research.

Translational research 2008 to 2018

In 2018, the MRC commissioned an independent review of our translational research investments. This evaluation showed strong evidence that MRC funding supported projects to progress along the developmental pathway and attract further funding for later stage development. Projects were found to have delivered a diverse range of outputs, including novel research tools, medical devices and therapeutics, which had been taken forward to be tested in later phase studies.

The review highlighted the significant contribution of MRC’s Impact Acceleration Accounts (IAA) and Developmental Pathway Funding Scheme (DPFS) in driving commercialisation and strengthening the UK’s translational research pipeline. Stakeholder feedback was overwhelmingly positive, recognising MRC’s role in fostering a stronger translational research culture across UK academia and supporting its growth.

Read the MRC report on translational research 2008 to 2018.

Spin-outs arising from MRC translational funding

In 2025, an independent evaluation was commissioned to establish an overview of the investment and growth outcomes achieved by spin-outs that have been linked to intellectual property developed with MRC’s funding.

Ipsos UK collected an initial dataset that included details of companies established to commercialise technologies linked to MRC-funded research from 2008 to 2023. One hundred and forty-six were linked to MRC’s translationally targeted research funding.

The report’s findings indicate that spin-outs arising from MRC’s translationally targeted research funding have been highly successful. They have leveraged £5.30 of external investment from every £1 invested, by raising approximately £3.1 billion of external equity investment between 2008 and 2023, relative to £577 million in research funding committed.

These spin-outs also attract more external funding in total, and on average raise greater levels of funding, than those associated with all other MRC-funded research.

Read the report on development and growth of spin-outs from MRC research.

Who to contact

General enquiries

Email: dpfsanddcs@mrc.ukri.org

We encourage you to get in touch with the relevant programme manager to discuss your proposal ideas.

Please ensure you include a description of the intervention you are planning to develop and the clinical need it is designed to target. Wherever possible, please include a one to two-page overview of the proposed project plan to enable us to provide the most appropriate advice and support.

Advanced treatments (not including cancer), including regenerative medicine, gene therapy, nucleic acid therapy, cell therapies and antibodies

Dr Claire De-May

Email: claire.de-may@mrc.ukri.org

Advanced treatments in cancer, including cancer vaccines, gene therapy, nucleic acid therapy, cell therapies, radiotherapy and antibodies

Dr Sophie Mountcastle

Email: sophie.mountcastle@mrc.ukri.org

Prevention of infectious diseases, including vaccines, diagnostics and challenge models

Dr Florence Theberge

Email: florence.theberge@mrc.ukri.org

Medical imaging, medical devices and digital health, including psychological interventions

Dr Yarunnessa Khan

Email: yarunnessa.khan@mrc.ukri.org

Non-communicable disease prevention and early diagnosis, including diagnostics, biomarkers and clinical decision-making

Diana Korniichuk

Email: diana.korniichuk@mrc.ukri.org

Medicines repurposing, protein and peptide therapeutics, non-small molecule drugs, nanomedicine, drug delivery technology, biomanufacturing

Dr Alicia Estacio-Gomez

Email: alicia.estaciogomez@mrc.ukri.org

Small molecules, AI-enabled drug discovery and development

Covered across the team

Email: dpfsanddcs@mrc.ukri.org

Governance, management and panels

The MRC Proof of Concept panel meets three times annually in January, May and September to assess applications and recommend awards for funding.

Find details of the current MRC Proof of Concept panel membership.

Last updated: 19 August 2026

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services.